Keywords: further, ph, ii, analysis, confirms, efficacy, ml
Further Ph II analysis confirms efficacy of ML's Devacade
Article | 21 August 2001
ML Laboratories has announced positive Phase II clinical trial data forits orally-administered selective cholecystokinin A receptor antagonist, Devacade (devazepide), as ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Aspen Pharma offers to buy GlaxoSmithKline's thrombosis brands and manufacturing site
- FDA probes two deaths possibly linked to Lilly's antipsychotic Zyprexa Relprevv
- Athera and Boehringer Ingelheim enter option agreement on a novel therapy for atherosclerosis
- US Supreme Court says patent settlement can "sometimes" be illegal
- Actavis and Kissei file law suits against Sandoz and Hetero over Rapaflo patent
